World Journal of Endocrine Surgery

Register      Login

VOLUME 14 , ISSUE 2 ( May-August, 2022 ) > List of Articles

Photo Essay

Use of Lenvatinib in Neoadjuvant Setting to Achieve Total Thyroidectomy in a Case of Inoperable Follicular Thyroid Carcinoma

Roma Pradhan, Mallika Dhanda, Navya M Kurian, Saumya Singh, Nasim Ahmad, Nidhi Anand

Keywords : Differentiated thyroid cancer, Endocrine surgery, Thyroid

Citation Information : Pradhan R, Dhanda M, Kurian NM, Singh S, Ahmad N, Anand N. Use of Lenvatinib in Neoadjuvant Setting to Achieve Total Thyroidectomy in a Case of Inoperable Follicular Thyroid Carcinoma. World J Endoc Surg 2022; 14 (2):66-67.

DOI: 10.5005/jp-journals-10002-1440

License: CC BY-NC 4.0

Published Online: 15-04-2023

Copyright Statement:  Copyright © 2022; The Author(s).


Abstract

Lenvatinib and other tyrosine kinase inhibitors (TKIs) are being used in locally advanced thyroid cancers like poorly differentiated and anaplastic, as well as in radiorefractory differentiated thyroid cancer (DTC). However, their role in the neoadjuvant setting for DTCs is being increasingly explored, but there are only anecdotal reports in the literature that too only for percutaneous transhepatic cholangiography (PTC). Our case seems to be the first case where it was used in follicular thyroid cancer in the neoadjuvant setting.


HTML PDF Share
  1. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372(7):621–630. DOI: 10.1056/NEJMoa1406470
  2. Cabanillas ME, Ryder M, Jimenez C. Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr Rev 2019;40(6):1573–1604. DOI: 10.1210/er.2019-00007
  3. Alshehri K, Alqurashi Y, Merdad M, et al. Neoadjuvant lenvatinib for inoperable thyroid cancer: a case report and literature review. Cancer Rep (Hoboken) 2022;5(2):e1466. DOI: 10.1002/cnr2.1466
  4. Iwasaki H, Toda S, Ito H, Nemoto D, et al. A case of unresectable papillary thyroid carcinoma treated with lenvatinib as neoadjuvant chemotherapy. Case Rep Endocrinol 2020;6438352. DOI: 10.1155/2020/6438352
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.